FOREST LABS DOES NOT OFFER SPECIAL MAIL ORDER DISCOUNTS
Executive Summary
FOREST LABS DOES NOT OFFER SPECIAL MAIL ORDER DISCOUNTS, the company's Exec VP-Marketing Phillip Satow maintained in an Aug. 27 letter to "The Pink Sheet." Commenting on a recent McKesson invoice indicating a 94% discount off AWP on the prices for two products ordered by one mail order client, Sadow asserted "that Forest Laboratories as a matter of policy does not contract with mail-order companies at discount prices." The McKesson invoice -- for an undisclosed customer with retail and mail order businesses -- was appended to testimony presented to Rep. Waxman's (D-Calif.) House Energy & Commerce/Health subcommittee by NARD in late July ("The Pink Sheet" Aug. 24, T&G-5). Forest says it did not pay the chargeback request from McKesson for the mail order discounts listed on the invoice. "It appears in this case," Satow explained, "that McKesson apparently made an error in discounting Forest products to a mail- order house and that Forest did not honor the discounted sale for precisely the reason that the customer was not entitled to a discount."
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth